衰老与阿尔茨海默病中β-淀粉样蛋白积累的时间动态
研究基于ADNI两样本(A组475例含认知正常、MCI和AD,B组220例认知正常Aβ-),用[18F]Florbetapir PET随访至9年。Aβ随时间呈S形积累,从阴性转阳性需6.4年,再经13.9年至MCI起病;阳性率38/1000人年,转化与年龄、基线FBP及女性APOE ε4携带相关。
要点
- Aβ PET从阴性转阳性约需6.4年,转阳后13.9年出现MCI。
- Aβ沉积速率在达阳性阈值后仅3.8年开始减慢。
- 认知正常Aβ-者FBP斜率与5年后记忆下降和tau相关。
核心结论
- 降低脑Aβ必须在AD演变早期完成,早期降低Aβ速率可能产生临床显著获益。
研究设计与样本
- 研究两样本来自阿尔茨海默病神经影像学倡议,用[18F]Florbetapir Aβ PET随访至9年。
- 样本A含475例认知正常老年人、MCI和AD患者,样本B含220例认知正常Aβ-个体。
主要发现
- 时间与脑Aβ关系呈S形,从淀粉样蛋白阴性转阳性需6.4年,再13.9年至MCI起病。
- Aβ沉积速率在达阳性阈值后仅3.8年开始减慢。
- 扫描阳性发生率38/1000人年,转化相关因素为年龄、基线FBP和女性APOE ε4携带。
- 认知正常Aβ-个体中,FBP斜率与基线后5年记忆下降速率和[18F]Flortaucipir PET脑tau相关。
临床怎么用
- 对Aβ-认知正常个体,PET转化可预测,宜早期考虑Aβ降低治疗。
- 女性APOE ε4携带者、高龄及基线FBP较高者转化风险更高,需密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand the time course of β-amyloid (Aβ) deposition in the brain, which is crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD). METHODS: Two samples of participants from the Alzheimer's Disease Neuroimaging Initiative were studied with [18F]Florbetapir (FBP) Aβ PET and followed for up to 9 years. Sample A included 475 cognitively normal (CN) older people and those with mild cognitive impairment (MCI) and AD and sample B included 220 CN Aβ- individuals. We examined the trajectory of FBP over time in sample A and the incidence rate of conversion from negative to positive Aβ PET scans in sample B. RESULTS: The relationship between time and brain Aβ was sigmoidal, taking 6.4 years to transition from amyloid negative to positive and another 13.9 years to the onset of MCI. Aβ deposition rates began to slow only 3.8 years after reaching the positivity threshold. The incidence rate for scan positivity was 38/1,000 person-years, and factors associated with conversion were age, baseline FBP, and being a female APOE ε4 carrier. Among CN Aβ- individuals, FBP slopes were associated with rates of memory decline and brain tau measured with [18F]Flortaucipir PET 5 years after baseline. CONCLUSIONS: Lowering brain Aβ must be accomplished early in the evolution of AD. Transitions of PET scans from Aβ- to Aβ+ should be predictable, and it is reasonable to expect that lowering rates of Aβ even in early stages could produce clinically significant benefits.
引用
- Jagust WJ, Landau SM. Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease. Neurology. 2021. PMID: 33408147. doi:10.1212/WNL.0000000000011524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。